I am glad to see they are addressing inflammation.

With Fourier and Improve-IT not showing a reduction in mortality despite improved lipid parameters, some focus must be turned to inflammation.

PCSK9 inhibitors don't drop hsCRP and Ezetimide mono therapy does not either (although statin combo does).

This could be a key differentiator that can lead to positive hard endpoint results for Apabetalone.

bfw